That's the reason for my earlier post. Again,why

That's the reason for my earlier post.

Again,why would they put out today's PR without having any confirming evidence that the trial(s) are succeeding?Putting the "cart before the horse"?

IMHO they could well be getting positive P21 data that they can't release as such (which would indicate positive P53 activity ,which  in turn,would lead the investment community to "assume" tumor shrinkage is in progress,etc).

But they could say it's working (indirectly) by showing that they are so confident in the results  that they are looking to "Fast Tracking" (In effect saying the trials are everything they hoped for)Where does one go to start figuring a realistic target?

I guess a reasonable starting point would be the market size for the particular cancer tumor involved in the trial and use that as a base?

Market reaction (or over reaction) is the 1 unknown here as well as the amount and type of media publicity exposure which could blow this thing wide open.

I know I tend to be an optimist but I have tried to play "devil's advocate" on this PR and can't see any valid reason to PR it without seeing"great progress" and then taking the risk of great embarrassment if the trials were just Ho-Hum.Also risking the current level of trust in their integrity to date.

Kelt